Aetna BNP/NT‑proBNP Coverage Update

Medically necessary indications

Covered when ANY of the following indications are present:

Indication 1: To differentiate dyspnea due to heart failure from pulmonary disease

Indication 2: To determine prognosis or disease severity in chronic heart failure

Indication 3: Measurement upon hospital admission to determine prognosis in persons with acutely decompensated heart failure

Experimental and investigational (Not covered)

Considered experimental and investigational for ALL other indications, including but not limited to:

Series of examples: Serial measurements of plasma BNP and/or NT-proBNP for indications such as: biomarker for cerebral small vessel disease/vascular brain damage in hypertension; biomarker for hypertensive disorders of pregnancy; biomarker for subclinical brain damage; cardiac biomarker for Friedreich ataxia; cardiovascular biomarker in healthy normal subjects; prognostic biomarker for acute coronary syndrome; prognostic biomarker related to anemia in sickle cell disease (NT-proBNP); prognostic biomarker for incident type 2 diabetes; prognostic biomarker of weaning outcome from mechanical ventilation; prognostic marker for structural congenital heart disease; detecting early cardiac dysfunction in chronic fatigue syndrome or tetralogy of Fallot; determining prognosis after acute coronary syndrome; diagnosing cardio-embolic stroke; diagnosing Kawasaki disease; diagnosing patent ductus arteriosus; diagnosing preeclampsia; diagnosing systemic sclerosis heart involvement; diagnosing or screening pulmonary hypertension associated with bronchopulmonary dysplasia; guiding statin decisions in HF; guiding thrombolytic therapy in acute PE; identifying individuals at risk of abnormal brain aging; managing members with chronic renal failure; monitoring effectiveness of therapy in congestive HF; predicting acute kidney injury after non-cardiac surgery; predicting cardiovascular complications after bariatric surgery; predicting fatal outcome after stroke; predicting outcome in congenital diaphragmatic hernia; predicting short-term mortality in sepsis; predicting occurrence of AF after cryptogenic stroke or thoracic surgery; pre-operative cardiac risk assessment in non-cardiac surgery; routine evaluation of dyspnea (other than to distinguish HF from pulmonary disease); risk stratification in aortic stenosis; screening for unrecognized LV dysfunction; titrating therapy for chronic HF, and other listed uses

See enumerated list in policy

Evidence summaries and context

Evidence-supported and investigated uses (summary of findings):

Diagnostic use for dyspnea: Measurement of BNP/NT-proBNP provides incremental diagnostic value in ambulatory settings for suspected cardiac dyspnea when cause is unclear and physical exam equivocal

ACC guideline statement supports diagnostic value

Prognostic use pre-discharge or outpatient: Predischarge BNP/NT-proBNP are strong predictors of death or readmission; changes reflect prognosis and adherence/optimization of GDMT but targeting specific thresholds to guide inpatient therapy lacks consistent evidence

Guidelines caution about targeting thresholds

BNP-guided therapy for chronic HF: Randomized trials and meta-analyses show BNP-guided therapy may reduce all-cause mortality overall (notably in patients <75 years) but results are mixed and not uniformly effective for hospitalization outcomes

Age interaction observed; benefit not seen ≥75 years

Cardio-embolic stroke identification

Diagnostic use of BNP/NT-proBNP for stroke subtype and cardio-embolic source — evidence-based criteria

BNP/NT-proBNP to support cardio-embolic stroke diagnosis: Use BNP or NT-proBNP to help differentiate cardio-embolic stroke from other ischemic stroke subtypes when combined with clinical evaluation and imaging; pooled sensitivity for BNP ~0.78 and specificity ~0.83, with NT-proBNP showing slightly higher specificitynot a single universal cutoff; interpret per study and assay

A single BNP-negative result may exclude CE stroke in low-prevalence (<20%) settings; timing and assay variability affect performance

hsPDA diagnosis (neonates)

Diagnosis of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants

NT-proBNP use for hsPDA: Measure NT-proBNP on day 3 in preterm infants as a marker for hsPDA; one study reported day 3 NT-proBNP AUC 0.978 with a proposed cutoff of 11,395 pg/ml (sensitivity 100%, specificity 95%)day 3 NT-proBNP >= 11,395 pg/ml

Echocardiography remains gold standard; assays should be locally validated

Kawasaki disease diagnosis

Diagnosis of Kawasaki disease (pediatric)

NT-proBNP for Kawasaki disease: NT-proBNP has moderate diagnostic accuracy for Kawasaki disease (pooled sensitivity ~0.80–0.89 and specificity ~0.72–0.81 across meta-analyses) and may aid diagnosis in prolonged undifferentiated febrile illness but should not be used alone to rule in or out KDno universal cutoff; varies by study and assay

Further well-designed prospective studies needed to define optimal cutoffs

Atrial fibrillation prognostic use

Prognostic/risk-stratification use in atrial fibrillation

NT-proBNP for AF risk stratification: NT-proBNP is independently associated with stroke, systemic embolism, and mortality in AF and adds prognostic value beyond the CHA2DS2-VASc score; quartile-based risk stratification (ARISTOTLE quartiles) demonstrated graded event ratesARISTOTLE quartiles used in studies (Q1 <=363 ng/L; Q2 364–713 ng/L; Q3 714–1,250 ng/L; Q4 >1,250 ng/L)

Treatment benefits of anticoagulation were independent of NT-proBNP level

CHD, ToF, and brain aging associations

Use in congenital heart disease and noncardiac aging outcomes

BNP/NT-proBNP in complex CHD and repaired ToF: BNP/NT-proBNP levels are frequently elevated in complex congenital heart disease and in adults with repaired tetralogy of Fallot and correlate with ventricular dilation and dysfunction, but absolute values vary widely across anomaly types and should be interpreted with imaging correlationno universal cutoff

Sequential measurement in large prospective studies recommended

NT-proBNP and brain aging: Higher NT-proBNP levels are associated with lower brain volumes and worse cognitive performance independent of cardiovascular risk factors and cardiac output in older adults, but clinical utility for screening is unestablishedno diagnostic threshold

Observational association only; further research needed

NT‑proBNP and abnormal brain aging

Identification of individuals at risk of abnormal brain aging — study findings

Association with brain structure and function: Higher NT‑proBNP levels were independently associated with lower total, gray matter and white matter brain volumes and worse cognitive scores and depressive symptoms in the AGES‑Reykjavik cohort; associations were independent of cardiac output

Cross‑sectional study; further research needed

Pre‑operative NP and AF risk

Pre-operative NP and postoperative atrial fibrillation

Pre‑op elevated NP predicts AF: An elevated pre‑operative natriuretic peptide measurement was associated with increased odds of post‑operative atrial fibrillation after thoracic surgery (pooled OR ~3.13; sensitivity analyses OR ~9.51), with thresholds varying across studiesvaried across studies

Heterogeneity present across studies; may augment AF risk prediction models

NT‑proBNP as part of biomarker panel in AS

Biomarker panel including NT‑proBNP and mortality after aortic valve replacement

Number of elevated biomarkers correlates with mortality: In patients undergoing AVR, three biomarkers (GDF15, sST2, NT‑proBNP) were retained in a prognostic model and increasing number of elevated biomarkers corresponded to higher 1‑year mortality (0:5%; 1:12%; 2:18%; 3:33%)median-based high vs low

Added prognostic value beyond STS risk score

BNP in preeclampsia

BNP association with cardiac ultrasound abnormalities in severe preeclampsia

BNP correlates with cardiac dysfunction markers: In late‑onset severe preeclampsia, BNP level was associated with systolic and diastolic dysfunction and elevated LVEDP; study was observational and not designed to change management

UpToDate review does not recommend BNP as diagnostic tool for preeclampsia

BNP in neonatal BPD‑associated PH screening

BNP as potential screening biomarker for BPD‑associated PH

Higher BNP associated with echocardiographic TR: In extremely preterm infants with BPD, BNP was higher in those with tricuspid regurgitation on echo at 36‑week corrected age (median 54.5 vs 41.5 pg/ml), suggesting potential screening role though further validation is needed

Echo remains diagnostic standard

Conditional/Contextual Use

Coverage considerations based on evidence excerpts in this section:

Context-specific utility: BNP/NT-proBNP may be useful in specific clinical contexts (e.g., to help rule in PH in preterm infants with severe BPD at cut‑point ~130 pg/ml; to provide prognostic information in sepsis at high cut‑points), but are not sufficient alone to diagnose conditions such as PH; test performance and recommended use vary by populationsee thresholds module

Serial measurements may be helpful for monitoring in select settings but are not universally recommended; assays should be locally validated

Evidence-supported clinical contexts

Contexts where BNP/NT-proBNP have evidence supporting diagnostic/prognostic use include the following findings from systematic reviews/meta-analyses:

Weaning from mechanical ventilation: Relative change in BNP (ΔBNP%) during a spontaneous breathing trial demonstrates high pooled sensitivity (~0.89) and specificity (~0.83) for predicting successful liberation from mechanical ventilation in adults with pooled AUROC ~0.92; no universally validated ΔBNP% cut‑off establishednot established—no universally validated ΔBNP% cut-off

Shows potential as incremental tool after successful SBT; requires prospective validation

Screening for left ventricular systolic dysfunction (LVSD): Pooled analyses suggest NT‑proBNP and BNP can detect LVSD with moderate‑high sensitivity and specificity in combined community and high‑risk populations; pooled optimal cut‑offs reported NT‑proBNP 311 pg/ml and BNP 49 pg/ml but significant heterogeneity existsNT-proBNP 311 pg/ml; BNP 49 pg/ml

Optimal thresholds in specific high‑risk populations remain uncertain; prospective studies needed

Routine measurement of BNP/NT-proBNP for evaluation of dyspnea is not covered except when used specifically to distinguish heart failure from pulmonary disease. Randomized trial evidence shows routine BNP testing of all severely dyspneic emergency department patients did not improve admission rates, length of stay, or initial management decisions, and therefore routine use across all dyspneic patients is not supported. Documentation should demonstrate that testing is intended to resolve diagnostic uncertainty between cardiac versus pulmonary causes of dyspnea.

Use of natriuretic peptides for screening of asymptomatic (healthy) populations is inappropriate and not supported by the evidence. In community-based cohorts referred to as "healthy normal," NT‑proBNP did not predict death or cardiovascular events; therefore NT‑proBNP is not recommended as a population screening test.

Guiding or titrating heart failure therapy based on BNP or NT‑proBNP (BNP‑guided therapy) is not established. Systematic reviews and randomized trials have heterogeneous designs and report low-quality, inconsistent evidence; meta-analyses have concluded the current evidence is insufficient to support routine use of BNP/NT‑proBNP to direct therapy decisions.

An UpToDate review does not recommend routine measurement of BNP for diagnostic or prognostic evaluation in hypertrophic cardiomyopathy, noting wide variability in values and poor correlation with symptoms; guideline recommendations may differ, but routine BNP measurement for HCM evaluation is not endorsed in this review.

BNP or NT‑proBNP alone are not sufficient to diagnose or exclude pulmonary hypertension associated with bronchopulmonary dysplasia (BPD). UpToDate advises that biomarker measurements may supplement but cannot replace echocardiography and clinical assessment; serial measurements may be used for monitoring but are not definitive diagnostic tests.

Elevations in BNP/NT‑proBNP are not specific to heart failure. Levels are influenced by age, sex, obesity, renal function and other conditions, and assay methods vary; therefore biomarker results must be interpreted in the clinical context and with awareness of assay variability.

This Clinical Policy Bulletin provides a general description of plan benefits and evidence summaries but is not a contract. It is informational and does not by itself guarantee coverage or create provider obligations beyond the terms of the individual member’s benefits and applicable contract language.

Serial BNP/NT‑proBNP measurements for indications other than the specifically enumerated medically necessary uses — including routine serial monitoring to titrate heart failure therapy — are considered investigational or not medically necessary. The available trials and reviews do not provide consistent, high‑quality evidence to support serial biomarker measurement for these non‑listed indications.

A randomized trial in acutely dyspneic emergency department patients found that routine BNP testing of all severely dyspneic patients did not change clinical outcomes or health services use. Consequently, routine BNP testing of every severely dyspneic ED patient is not supported as standard practice.

BNP‑guided therapeutic titration for chronic heart failure remains supported only by mixed, low‑quality evidence. Systematic reviews note heterogeneity among trials and imprecision in outcomes, and conclude the evidence is insufficient to recommend routine BNP‑guided management for chronic heart failure patients.

In the cited pediatric studies of congenital diaphragmatic hernia, NT‑proBNP and high‑sensitivity troponin T did not predict major clinical outcomes such as severe pulmonary hypertension, death, need for ECMO, or bronchopulmonary dysplasia, and therefore these biomarkers were not demonstrated to be reliable prognostic markers for those endpoints in that cohort.

An UpToDate review on preeclampsia does not list serum BNP measurement as a diagnostic tool. Although some observational studies report associations between BNP and echocardiographic abnormalities in severe preeclampsia, current guidance does not recommend routine use of BNP for diagnosing preeclampsia.

The evidence is insufficient to support BNP/NT‑proBNP as definitive standalone diagnostic tests for systemic sclerosis heart involvement or systemic sclerosis–associated pulmonary arterial hypertension. Systematic reviews report heterogeneous definitions, variable study quality, and only moderate pooled sensitivity and specificity, indicating these biomarkers may be adjunctive but are inadequate alone for diagnosis.

Billing and Diagnostic Codes

Covered CPT Codes (if selection criteria met)CPTCovered

83880

Natriuretic peptide

ICD-10 codes covered when selection criteria are metICD-10

I50.1 - I50.9	Heart failure
J40 - J47.9	Chronic lower respiratory diseases
R06.00 - R06.09	Dyspnea
R06.82	Tachypnea, not elsewhere classified

ICD-10 codes called out as not covered for specific indicationsICD-10Not Covered

A02.1	Not covered — Sepsis and multiple listed codes
D57.0 - D57.819	Sickle-cell disorders (not covered for related listed indication)
E11.00 - E13.9	Diabetes mellitus, type II (not covered for listed indication)
I12.0 - I13.2	Hypertensive chronic kidney disease / hypertensive heart and chronic kidney disease (not covered for management of chronic renal failure)
I20.0 - I25.9	Ischemic heart diseases (not covered for identification of stress-induced myocardial ischemia or cardio-embolic stroke)
N18.1 - N18.9	Chronic kidney disease (not covered for managing chronic renal failure)
O14.00 - O14.95	Pre-eclampsia (not covered for diagnosing preeclampsia)
Q20.0 - Q28.9	Congenital malformations of the circulatory system (not covered for certain congenital indications)
Z01.810	Encounter for preprocedural cardiovascular examination (not covered for pre-operative cardiac risk assessment in non-cardiac surgery)

Covered CPT CodesCPT

No codes listed

No specific billing codes listed in this excerptmixed

No codes listed

BNP diagnostic threshold — evidence

BNP diagnostic threshold> 100 pg/ml

ContextPlasma BNP >100 pg/ml reported to support diagnosis of symptomatic heart failure; levels influenced by age, sex, and diastolic dysfunction.

pro‑BNP threshold for AF detection after cryptogenic stroke

pro‑BNP threshold (cryptogenic stroke)>= 360 pg/ml

Clinical implicationpro‑BNP >=360 pg/ml associated with 5-fold increased odds of later AF detection after cryptogenic stroke (OR 5.70).

NT‑proBNP threshold for hsPDA (preterm infants)

NT‑proBNP day 3 cutoff (hsPDA)11,395 pg/ml (sensitivity 100%, specificity 95%)

Study noteDay 3 NT‑proBNP had AUC 0.978 for detecting hemodynamically significant PDA; echocardiography remains gold standard.

ARISTOTLE NT‑proBNP quartiles

ARISTOTLE NT‑proBNP quartilesQ1 ≤ 363 ng/L; Q2 364–713 ng/L; Q3 714–1,250 ng/L; Q4 > 1,250 ng/L

Prognostic useHigher quartiles associated with increased rates of stroke, systemic embolism, and cardiac death; added discrimination beyond CHA2DS2‑VASc.

BNP level used in subgroup comparisons

BNP subgroup cutoff used in CFS study400 pg/ml

FindingBNP >400 pg/ml associated with lower cardiac volumes in chronic fatigue syndrome cohort compared with BNP <400 pg/ml.

BNP median in infants with TR (BPD cohort)

Median BNP in infants with TR vs without54.5 pg/ml versus 41.5 pg/ml (median; IQRs reported)

ContextHigher BNP associated with echocardiographic tricuspid regurgitation at 36‑week corrected age in extremely preterm infants with BPD.

BNP cut-point for PH in preterm infants with sBPD

BNP optimal cut‑point for PH in sBPD130 pg/ml (specificity 92%, sensitivity 50%)

Diagnostic performanceAUC 0.74; BNP better at ruling in pulmonary hypertension (high specificity) than ruling it out in this cohort.

BNP / NT‑proBNP cutoffs for short‑term mortality in sepsis

Cutoffs predicting short‑term mortality in sepsisBNP 622 pg/ml; NT‑proBNP 4,000 pg/ml

PerformanceThese cutoffs had greatest discrimination in pooled analysis (BNP AUC ~0.77, NT‑proBNP AUC ~0.79); timing of specimen influences discrimination.

NT‑proBNP screening threshold in bariatric surgery cohort

NT‑proBNP screening threshold (bariatric cohort)>=125 pg/ml — used to trigger further cardiac evaluation (ECG, echocardiography)

Cohort outcome23% of patients ≥50 years had elevated NT‑proBNP prompting further work-up; ECG and echo identified AF and structural/functional abnormalities.

BNP cut‑off in hypertensive disorders of pregnancy

BNP cut‑off in hypertensive pregnancy cohort50.81 pg/ml (AUC 0.902)

InterpretationBNP discriminated hypertensive disorders of pregnancy from controls in this study; not established as diagnostic standard.

Screening thresholds for LV systolic dysfunction (combined populations)

Screening thresholds for LV systolic dysfunction (pooled)NT‑proBNP 311 pg/ml; BNP 49 pg/ml

PerformanceNT‑proBNP 311 pg/ml (sensitivity 0.74, specificity 0.85); BNP 49 pg/ml (sensitivity 0.68, specificity 0.81); heterogeneity between studies noted.

Predictive performance threshold for ΔBNP%

Predictive performance for ΔBNP%No validated universal ΔBNP% threshold — pooled AUROC reported 0.92 but lacks prospective validation

ImplicationRelative change in BNP during SBT shows high discrimination for successful liberation from mechanical ventilation but needs prospective threshold validation.

Ordering, Documentation, and Authorization Guidance

Prior Authorization

Prior authorization — clinical indication required

Prior authorization — clinical indication required. Testing (CPT 83880) is covered only when clinically indicated; ensure the order includes a documented clinical indication (examples: unexplained/acute dyspnea to distinguish heart failure from pulmonary disease, outpatient evaluation of suspected cardiac cause of dyspnea, pre-operative risk evaluation when clinically warranted). Claims should link to appropriate ICD-10 diagnosis codes that support a medically necessary indication.

Affected CPT: 83880 (natriuretic peptide) — covered when selection criteria are met
Document clinical context: unexplained dyspnea, acute/urgent setting, outpatient evaluation for suspected HF, or other medically necessary indications supported in policy

Note

Prior authorization not specified

Prior authorization not specified in excerpts. Several background and evidence sections describe clinical uses, limitations, and coding guidance, but no explicit universal prior authorization program or pre-certification requirement is described in the provided policy fragments.

No prior authorization process detailed in the shown excerpts
Providers should follow plan-specific prior auth workflows if present elsewhere

Denial Risk

Investigational indications trigger denial

Investigational/experimental indications will trigger denial. Serial measurements and many listed uses (e.g., screening asymptomatic populations, titrating therapy for chronic HF, use as a biomarker for hypertensive disorders of pregnancy, Kawasaki disease, preeclampsia, systemic sclerosis heart involvement, pulmonary hypertension associated with BPD, and multiple other indications listed in the policy) are considered experimental and investigational and are not covered.

Serial BNP/NT-proBNP measurements for indications other than those explicitly deemed medically necessary are experimental/investigational and may be denied
Examples of investigational uses: titrating HF therapy, routine screening, numerous diagnostic/prognostic uses listed in policy

Documentation Required

Low-quality evidence for BNP-guided HF therapy

Low-quality or insufficient evidence exists for BNP/NT-proBNP–guided heart failure therapy. Systematic reviews and guideline statements note heterogeneity across trials and limited or inconsistent outcome benefit from biomarker-guided titration compared with symptom-guided care; evidence is therefore considered low quality and inadequate to mandate biomarker-guided therapy.

Meta-analyses and guidelines report inconsistent results and heterogeneity across trials
BNP-guided titration has not been consistently shown to improve outcomes compared with usual care

Note

No explicit authorization or coverage rules in excerpts

No explicit authorization or coverage rules are specified in the provided excerpts beyond the clinical indications and investigational exclusions. Coverage determinations depend on meeting the medically necessary indications and appropriate coding; refer to the full policy for any operational coverage rules not present here.

Coverage is tied to medically necessary indications listed in policy
Operational authorization rules (if any) are not present in these fragments

Documentation Required

Insufficient as sole diagnostic test

BNP/NT-proBNP is insufficient as a sole diagnostic test in several contexts. Guidelines and reviews emphasize that natriuretic peptide levels should not replace standard clinical assessment or imaging (e.g., echocardiography) and are not a stand-alone diagnostic for conditions such as pulmonary hypertension, systemic sclerosis–associated PAH, or bronchopulmonary dysplasia–associated PH.

Do not use BNP/NT-proBNP in isolation to diagnose/exclude pulmonary hypertension or SSc-PAH
Use alongside imaging and clinical risk scores (echo, ECG, clinical assessment)

Note

No explicit prior authorization or denial trigger specified

No explicit prior authorization or denial trigger is present in these fragments; examples of denial risk are tied to investigational indications and lack of clinical documentation that supports a medically necessary indication.

Denials likely when testing is ordered for investigational/unlisted indications or without supporting documentation
Providers should document clinical rationale and link claims to appropriate ICD-10 codes

Documentation Required

Support clinical indication and diagnosis coding

Support clinical indication and diagnosis coding. Providers must document the clinical indication (e.g., unexplained acute dyspnea, suspected HF, prognostic assessment in acute decompensated HF) and submit appropriate ICD-10 diagnosis codes that align with medically necessary indications to support coverage.

Ensure claim links CPT 83880 to an ICD-10 code supporting HF or dyspnea due to suspected cardiac cause (examples: I50.x series, relevant R06.x codes when used to distinguish HF from pulmonary disease)
Document timing, clinical context, and intended clinical use in the medical record

Note

Data capture in preeclampsia study

Data capture in preeclampsia study. When BNP was collected in observational cohorts (e.g., preeclampsia studies), investigators recorded BNP along with echocardiographic findings and other clinical measures; elevated BNP in these cohorts was associated with cardiac dysfunction and other imaging abnormalities but clinical utility remains unclear.

Example study: cohort of 95 women with late-onset severe preeclampsia measured BNP, POCUS findings, and echocardiographic parameters
Policy notes that these data are preliminary and the clinical application of BNP in preeclampsia is unclear

Documentation Required

Referral trigger for further cardiac work-up

Referral trigger for further cardiac work-up. Elevated NT-proBNP in certain screening contexts (for example, pre-operative bariatric surgery screening) prompted further cardiac evaluation (ECG, echocardiography) and occasionally led to diagnosis and intervention; providers should use elevated results to guide additional diagnostic steps when clinically appropriate.

Example threshold used in cited cohort: NT-proBNP ≥125 pg/mL prompted ECG and echocardiography and led to further diagnoses in some patients
Use biomarker results to trigger appropriate follow-up testing, not as sole determinant of intervention

Step Therapy

Step therapy — none specified

Step therapy: none specified. No formal step-therapy cascade is described in these policy excerpts. Serial measurements or biomarker-guided cascades are not mandated as a requirement; evidence summaries do not establish a required stepwise approach to testing or treatment.

No step therapy or mandatory sequencing described in these sections
Serial measurements may be used selectively in monitoring, but are considered investigational for many indications

Definitions and Key Terms

Definition — BNP

BNP definitionB‑type (brain) natriuretic peptide — a 32‑amino acid cardiac peptide produced by the ventricles and used as a biomarker for heart failure.

Clinical notePlasma BNP levels correlate with left ventricular dysfunction but are influenced by age, sex, and other factors.

Definition — NT‑proBNP

NT‑proBNP definitionN‑terminal pro‑B‑type natriuretic peptide — inactive N‑terminal fragment of proBNP measured as a cardiac biomarker; longer half‑life than BNP.

ContextUsed alongside BNP for diagnosis and prognostic assessment in heart failure and other settings; assay and timing affect interpretation.

Definition — GDMT (guideline‑directed medical therapy)

GDMTGuideline‑directed medical therapy — evidence‑based pharmacologic and device therapies for heart failure referenced in guideline discussions.

Role in policyBNP/NT‑proBNP changes may reflect adherence/optimization of GDMT but using biomarker targets to direct therapy lacks consistent evidence.

Definition — BNP‑guided therapy

BNP‑guided therapy — definitionA treatment titration strategy that adjusts heart failure therapy based on BNP or NT‑proBNP levels with the goal of reaching biomarker targets.

Evidence noteGuidelines state the value of serial BNP measurements to guide therapy is not well established; randomized trials show mixed outcomes.

BNP / NT‑proBNP — characteristics and measurement contexts

Circulating natriuretic peptidesBNP and NT‑proBNP are cardiac peptides released with ventricular stress; NT‑proBNP is an inactive fragment with longer half‑life often measured clinically.

Measurement contextsAssay method, timing, and patient factors (age, renal function, obesity) influence levels and interpretation.

Definition — Cardio‑embolic (CE) stroke

Cardio‑embolic (CE) stroke definitionIschemic stroke subtype commonly due to cardiac sources (e.g., atrial fibrillation); BNP/NT‑proBNP elevations help differentiate CE stroke from other ischemic subtypes.

Diagnostic performancePooled BNP sensitivity ~0.78 and specificity ~0.83 for CE stroke; NT‑proBNP shows slightly higher specificity.

Measurement contexts for NT‑proBNP / BNP

Measurement contexts referencedBNP/NT‑proBNP measured in plasma/serum across studies evaluating stroke, neonatal hsPDA, BPD‑PH, sepsis mortality, pre‑operative screening, and brain aging.

Interpretive cautionAssay variability and population differences require local validation and documentation of assay method and timing.

Definition — Pulmonary hypertension (PH) in sBPD studies

PH definition in sBPD studiesPulmonary hypertension defined as right ventricular pressure > 1/2 systemic BP estimated from TR jet or PDA velocity, bi‑directional or right‑to‑left PDA, and/or flat/bowing ventricular septum at end‑systole.

ApplicationThis echocardiographic definition was the reference standard for BNP diagnostic accuracy analyses in sBPD cohorts.

Definition — Short‑term mortality endpoints (sepsis studies)

Short‑term mortality endpointsIncludes ICU, in‑hospital, 28‑day, or 30‑day mortality as used in pooled sepsis analyses.

ContextBNP/NT‑proBNP cutoffs reported for predicting short‑term mortality used these endpoints in pooled studies.

Definition — ΔBNP% (relative BNP change during SBT)

ΔBNP% definitionRelative change in BNP during a spontaneous breathing trial (SBT) used to predict successful liberation from mechanical ventilation.

EvidencePooled analyses report high sensitivity and specificity and AUROC (~0.92) for ΔBNP% but no universally validated percent‑change threshold.

Definition — SSc‑PAH (systemic sclerosis‑associated PAH)

SSc‑PAHPulmonary arterial hypertension secondary to systemic sclerosis; BNP/NT‑proBNP elevated in SSc‑PAH but biomarkers are not sufficient as standalone diagnostics.

PerformancePooled sensitivity ~0.67 and specificity ~0.84 for BNP/NT‑proBNP in SSc‑PAH diagnostic meta‑analysis.

ACC/AHA/HFSA guideline (reference)

ACC/AHA/HFSA guideline reference2017 focused update of the ACCF/AHA 2013 Guideline for Management of Heart Failure cited as guideline basis.

Guideline recommendationsRecommend measuring natriuretic peptides in patients with dyspnea for diagnosis and to determine prognosis; serial testing to guide therapy remains unestablished.

OpenPayer

Brain Natriuretic Peptide (BNP) Testing

Coverage and Investigational Determinations

Billing and Diagnostic Codes

Ordering, Documentation, and Authorization Guidance

Clinical and Scientific Background

Definitions and Key Terms

Policy Dates and Revision Notes